|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,341.50 GBX | +0.49% |
|
-0.37% | -7.50% |
| Dec. 02 | Berenberg Lowers Price Target on GSK to GBP16 From GBP18.20, Maintains Buy Rating | MT |
| Dec. 02 | GSK : Berenberg reiterates its Buy rating | ZD |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Capitalization | 54.74B 69.26B 65.95B 61.41B 97.24B 5,863B 107B 761B 282B 2,403B 261B 254B 10,356B | P/E ratio 2024 * |
14.9x | P/E ratio 2025 * | 9.51x |
|---|---|---|---|---|---|
| Enterprise value | 68.5B 86.67B 82.53B 76.84B 122B 7,337B 134B 953B 353B 3,008B 326B 318B 12,959B | EV / Sales 2024 * |
2.2x | EV / Sales 2025 * | 2.06x |
| Free-Float |
94.54% | Yield 2024 * |
4.5% | Yield 2025 * | 4.79% |
More valuation ratios
* Estimated data
More news
Last Transcript: GSK plc
More recommendations
More press releases
More news
| 1 day | +0.49% | ||
| 1 week | -0.04% | ||
| Current month | +0.49% | ||
| 1 month | -5.49% | ||
| 3 months | -19.04% | ||
| 6 months | -24.06% | ||
| Current year | -7.50% |
1 week
1 324.14
1 351.50
1 month
1 282.501 421.00
Current year
1 282.501 823.50
1 year
1 282.501 823.50
3 years
1 280.923 408.16
5 years
1 280.923 408.16
10 years
1 280.923 408.16
| Director | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 2017-03-31 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
BRD | Director/Board Member | 55 | 2016-12-31 |
Jesse Goodman
BRD | Director/Board Member | 72 | 2015-12-31 |
Hal Barron
BRD | Director/Board Member | 62 | 2017-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.17% | 11 M€ | +0.83% | - | |
| 3.15% | 20 M€ | +15.66% | - | |
| 2.97% | 55 M€ | +4.78% | - | |
| 2.51% | 8 M€ | +4.32% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +0.49% | -0.04% | -6.58% | -30.37% | 69.21B | ||
| +0.56% | +6.92% | +36.94% | +221.04% | 716B | ||
| +2.44% | +3.32% | +11.03% | +117.89% | 474B | ||
| -0.14% | -0.24% | -2.26% | -2.07% | 373B | ||
| -0.63% | +2.72% | +26.75% | +56.82% | 323B | ||
| -1.01% | +1.44% | -2.75% | +35.16% | 257B | ||
| +0.27% | +0.75% | +6.93% | -29.96% | 233B | ||
| -0.14% | -0.58% | +9.09% | +25.46% | 211B | ||
| -0.55% | +0.76% | +3.49% | +26.94% | 209B | ||
| -1.69% | -5.58% | +2.07% | +38.50% | 152B | ||
| Average | -0.07% | +0.98% | +8.47% | +45.94% | 301.84B | |
| Weighted average by Cap. | +0.17% | +2.08% | +14.22% | +82.37% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 31.17B 39.44B 37.56B 34.97B 55.37B 3,339B 60.9B 434B 161B 1,369B 148B 145B 5,897B | 32.27B 40.83B 38.88B 36.2B 57.33B 3,457B 63.05B 449B 166B 1,417B 154B 150B 6,106B |
| Net income | 3.67B 4.65B 4.43B 4.12B 6.53B 394B 7.18B 51.11B 18.96B 161B 17.5B 17.08B 695B | 5.79B 7.33B 6.98B 6.5B 10.29B 620B 11.31B 80.55B 29.88B 254B 27.58B 26.91B 1,096B |
| Net Debt | 13.76B 17.41B 16.58B 15.44B 24.44B 1,474B 26.88B 191B 70.98B 604B 65.52B 63.94B 2,603B | 11.64B 14.73B 14.02B 13.06B 20.68B 1,247B 22.74B 162B 60.04B 511B 55.42B 54.08B 2,202B |
More financial data
* Estimated data
Employees
70,212
Sector
Pharmaceuticals
Calendar
2024-12-03
- Evercore ISI HealthCONx Conference
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-02 | 1,341.50 p | +0.49% | 5,012,838 |
| 24-11-29 | 1,335.00 p | -0.41% | 4,678,466 |
| 24-11-28 | 1,340.50 p | -0.26% | 4,238,885 |
| 24-11-27 | 1,344.00 p | +0.45% | 4,017,467 |
| 24-11-26 | 1,338.00 p | -0.63% | 5,805,075 |
Delayed Quote London S.E., December 02, 2024 at 11:35 am EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
13.35GBP
Average target price
18.17GBP
Spread / Average Target
+36.14%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock